Aimei Health Technology Co Ltd - Tradeable Rights - Nov 2028 EBIT

The latest EBIT for AFJKR is $-2.2K as of March 2026. That compares with $-1.1M in the prior-year period — up 99.8% year over year. That is above the sector sector average of $-63M. Investors often review this figure alongside Aimei Health Technology Co Ltd - Tradeable Rights - Nov 2028's historical trend and sector peers before judging valuation or financial health.

Over the past year, AFJKR's EBIT moved from $-1.1M to $-2.2K — a 99.8% year-over-year increase. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Aimei Health Technology Co Ltd - Tradeable Rights - Nov 2028's operating scale or balance-sheet position.

Against its sector companies, AFJKR currently prints $-2.2K for EBIT, while the sector average sits near $-63M. That is roughly 100.0% above the sector mean. Large gaps often invite a closer look at Aimei Health Technology Co Ltd - Tradeable Rights - Nov 2028's growth, margins, and balance sheet.

A EBIT figure of $-2.2K for AFJKR is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. The sector average is about $-63M. Explore the charts below for those layers of context.

After noting AFJKR's EBIT ($-2.2K), review year-over-year change from $-1.1M, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.